Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Govorestat in CMT-SORD
NCT07191912Phase 3Withdrawn
- Sponsor
- Applied Therapeutics, Inc.
- Start
- May 2026
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in Sorbitol Dehydrogenase Deficiency (SORD) comparing Govorestat with Placebo (2 arms). Primary endpoint: Charcot-Marie-Tooth Health Index Total Score at 36 months. Planned start May 2026; status: withdrawn.
02
Drugs
govorestat
03
Conditions
Sorbitol Dehydrogenase Deficiency (SORD)
Beyond the preview
Go deeper on NCT07191912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07191912.